Literature DB >> 27155556

Continuing Decrease in Hepatitis B Virus Infection 30 Years After Initiation of Infant Vaccination Program in Taiwan.

Yen-Hsuan Ni1, Mei-Hwei Chang2, Chyi-Feng Jan3, Hong-Yuan Hsu4, Huey-Ling Chen4, Jia-Feng Wu4, Ding-Shinn Chen5.   

Abstract

BACKGROUND & AIMS: Taiwan began a universal hepatitis B virus (HBV) vaccination program for infants in July 1984. The seroprevalence of hepatitis B surface antigen (HBsAg) decreased from 9.8% before the vaccination program to less than 1% by 25 years afterward. We continued to monitor HBV infections in this population.
METHODS: We conducted a series of serologic and epidemiologic surveys in the Taipei metropolitan area every 5 years from 1984 through 2014. From January 1 through December 31 of 2014, we collected serum samples from 4605 apparently healthy individuals (ages: 287 were <3 y, 405 were 3-6 y, 675 were 7-12 y, 686 were 13-18 y, 468 were 18-22 y, and 2084 were 22-50 y). All subjects were tested for HBsAg, its antibody (anti-HBs), and hepatitis B core antibody (anti-HBc). We performed genotype and viral load analyses for patients who tested positive for anti-HBc.
RESULTS: Of vaccinated participants (age, <30 y; n = 3299), 0.5% tested positive for HBsAg, 47.4% tested positive for anti-HBs, and 4.5% tested positive for anti-HBc. Of unvaccinated participants (age, 30-50 y, n = 1306), 6.7% tested positive for HBsAg (P < .0001), 69.4% tested positive for anti-HBs, and 44.1% tested positive for anti-HBc. One occult HBV infection was found in each age group. Among subjects positive for HBsAg younger than age 30, 77% were born to mothers positive for HBsAg.
CONCLUSIONS: Based on a series of serologic and epidemiologic surveys performed in the Taipei metropolitan area, 6.7% of persons born before the universal HBV vaccination program were positive for HBsAg, compared with 0.5% of those born afterward. Most subjects positive for HBsAg younger than age 30 were born to mothers positive for HBsAg.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Immunization; Liver Disease; Prevention; Seroepidemiology

Mesh:

Substances:

Year:  2016        PMID: 27155556     DOI: 10.1016/j.cgh.2016.04.030

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  17 in total

1.  The impact of national viral hepatitis therapy program and hepatitis B vaccination program on mortality from acute and chronic viral hepatitis in Taiwan.

Authors:  Shih-Yung Su
Journal:  Hepatol Int       Date:  2019-01-31       Impact factor: 6.047

Review 2.  Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.

Authors:  Shiv K Sarin; Manoj Kumar; Mohammed Eslam; Jacob George; Mamun Al Mahtab; Sheikh M Fazle Akbar; Jidong Jia; Qiuju Tian; Rakesh Aggarwal; David H Muljono; Masao Omata; Yoshihiko Ooka; Kwang-Hyub Han; Hye Won Lee; Wasim Jafri; Amna S Butt; Chern H Chong; Seng G Lim; Raoh-Fang Pwu; Ding-Shinn Chen
Journal:  Lancet Gastroenterol Hepatol       Date:  2019-12-15

3.  The Asian American Network for Cancer Awareness, Research, and Training (AANCART)'s contributions toward reducing Asian American cancer health disparities, 2000-2017.

Authors:  Moon S Chen; Edward A Chow; Tung T Nguyen
Journal:  Cancer       Date:  2018-04-01       Impact factor: 6.860

4.  Association of Nationwide Hepatitis B Vaccination and Antiviral Therapy Programs With End-Stage Liver Disease Burden in Taiwan.

Authors:  Chun-Ju Chiang; Jing-Rong Jhuang; Ya-Wen Yang; Bo-Zhi Zhuang; San-Lin You; Wen-Chung Lee; Chien-Jen Chen
Journal:  JAMA Netw Open       Date:  2022-07-01

5.  Hepatitis B vaccine development and implementation.

Authors:  Hong Zhao; Xiaoying Zhou; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2020-03-18       Impact factor: 3.452

6.  Requirement for further validation on the seroconversion of hepatitis B surface antigen in successful vaccinees.

Authors:  Qing-Lei Zeng; Yi-Hua Zhou
Journal:  Hum Vaccin Immunother       Date:  2021-05-14       Impact factor: 3.452

7.  Progress towards elimination goals for viral hepatitis.

Authors:  Andrea L Cox; Manal H El-Sayed; Jia-Horng Kao; Jeffrey V Lazarus; Maud Lemoine; Anna S Lok; Fabien Zoulim
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-07-23       Impact factor: 46.802

8.  Seroprevalence of hepatitis B virus in Taiwan 30 years after the commencement of the national vaccination program.

Authors:  Yang-Cheng Hu; Chih-Ching Yeh; Ruey-Yu Chen; Chien-Tien Su; Wen-Chang Wang; Chyi-Huey Bai; Chi-Fei Chan; Fu Hsiung Su
Journal:  PeerJ       Date:  2018-02-16       Impact factor: 2.984

Review 9.  Long-term impact of infant immunization on hepatitis B prevalence: a systematic review and meta-analysis.

Authors:  Kate Whitford; Bette Liu; Joanne Micallef; J Kevin Yin; Kristine Macartney; Pierre Van Damme; John M Kaldor
Journal:  Bull World Health Organ       Date:  2018-05-14       Impact factor: 9.408

Review 10.  Chronic Viral Hepatitis: Current Management and Future Directions.

Authors:  Albert Do; Nancy S Reau
Journal:  Hepatol Commun       Date:  2020-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.